Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2001 Feb;49(12):671–678. doi: 10.1007/s002620000163

The self peptide annexin II (208–223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells

Susanne Heinzel 1, Delphine Rea 2, Rienk Offringa 2, Graham Pawelec 1
PMCID: PMC11036975  PMID: 11258793

Abstract

Annexin II is known to be over-expressed in different types of tumours. We show here that annexin II protein is expressed by melanoma cell lines in various amounts, consistent with previous findings that an annexin II (208–223) peptide could be eluted from isolated HLA-DR molecules of a constitutively MHC class II-positive melanoma line. T cells sensitized to annexin II (208–223) in vitro using peptide-pulsed autologous dendritic cells responded only to the lines which over-expressed annexin II, in a peptide-specific, HLA-DR-restricted fashion. These CD4+ T cells proliferated strongly and secreted large amounts of type 1 cytokines in response to annexin II (208–223) peptide or annexin II protein-positive melanoma cell lines. These results demonstrate that the annexin II (208–223) peptide, corresponding to a non-mutated sequence of a normal protein, induces antigen-specific T cells which can respond to melanoma cells over-expressing the annexin II molecule. This peptide may therefore be useful in immunotherapy for recruiting CD4+ type 1 helper cells active locally in the tumour environment.

Keywords: Key words Cancer immunotherapy, MHC class II-binding peptides, Annexin II (208, 223), Tumour immunology, CD4+ T cells

Footnotes

Received: 3 August 2000 / Accepted: 19 October 2000


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES